274 related articles for article (PubMed ID: 9748525)
1. Clinical applications of the camptothecins.
Takimoto CH; Wright J; Arbuck SG
Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
[TBL] [Abstract][Full Text] [Related]
2. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
3. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Lavergne O; Bigg DC
Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
[TBL] [Abstract][Full Text] [Related]
4. The development of camptothecin analogs in childhood cancers.
Bomgaars L; Berg SL; Blaney SM
Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
6. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Garcia-Carbonero R; Supko JG
Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of topoisomerase I inhibitors in anticancer treatment.
Rodriguez-Galindo C; Radomski K; Stewart CF; Furman W; Santana VM; Houghton PJ
Med Pediatr Oncol; 2000 Oct; 35(4):385-402. PubMed ID: 11025469
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
[TBL] [Abstract][Full Text] [Related]
10. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
11. [A symphony for the camptothecins].
Lansiaux A; Bailly C
Bull Cancer; 2003 Mar; 90(3):239-45. PubMed ID: 12801826
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase I inhibitors: review and update.
Rothenberg ML
Ann Oncol; 1997 Sep; 8(9):837-55. PubMed ID: 9358934
[TBL] [Abstract][Full Text] [Related]
13. Camptothecins: a review of their chemotherapeutic potential.
Ulukan H; Swaan PW
Drugs; 2002; 62(14):2039-57. PubMed ID: 12269849
[TBL] [Abstract][Full Text] [Related]
14. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
[TBL] [Abstract][Full Text] [Related]
15. Current perspectives on camptothecins in cancer treatment.
Dancey J; Eisenhauer EA
Br J Cancer; 1996 Aug; 74(3):327-38. PubMed ID: 8695345
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
17. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Vassal G; Pondarré C; Boland I; Cappelli C; Santos A; Thomas C; Lucchi E; Imadalou K; Pein F; Morizet J; Gouyette A
Biochimie; 1998 Mar; 80(3):271-80. PubMed ID: 9615866
[TBL] [Abstract][Full Text] [Related]
18. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
[TBL] [Abstract][Full Text] [Related]
19. An overview on the development of new potentially active camptothecin analogs against cancer.
Chazin Ede L; Reis Rda R; Junior WT; Moor LF; Vasconcelos TR
Mini Rev Med Chem; 2014; 14(12):953-62. PubMed ID: 25355593
[TBL] [Abstract][Full Text] [Related]
20. The clinical pharmacology of topoisomerase I inhibitors.
Abang AM
Semin Hematol; 1998 Jul; 35(3 Suppl 4):13-21. PubMed ID: 9779877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
